Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986166 PK interaction with oral contraceptives
NCT04934696Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of udifitimod in atopic dermatitis (AD) and autoimmune diseases, sponsored by Bristol Myers Squibb. Primary endpoints: Geometric means ratio of Cmax of NET, Geometric means ratio of Cmax of EE and 4 more. Started Aug 2021; status: completed.
02
Drugs
udifitimod
03
Conditions
atopic dermatitis (AD)autoimmune diseases
Beyond the preview
Go deeper on NCT04934696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934696.